)
Brii Biosciences (2137) investor relations material
Brii Biosciences H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Advanced core HBV functional cure program with three fully enrolled Phase II-B studies (ENSURE, ENRICH, ENHANCE), targeting viral suppression, immune restoration, and optimal combination regimens for chronic HBV treatment.
Out-licensed soralimixin (BRII-693) to Joincare Group for Greater China, focusing resources on HBV and seeking global partners for non-core assets.
Maintained a strong cash position, supporting late-stage development and early discovery pipeline through 2028.
Strategic partnerships and licensing agreements are expanding the pipeline and addressing antimicrobial resistance.
Repurchased 12,723,500 shares for HK$18.2 million, reflecting confidence in business outlook.
Financial highlights
Cash and cash equivalents as of June 30, 2025, were RMB2,075.3 million, down 14% from year-end 2024, supporting operations through 2028.
Other income for H1 2025 was RMB28.1 million, down 60.4% year-over-year, mainly due to lower interest income and reduced government grants.
R&D expenses declined 7.3% year-over-year to RMB117.0 million, reflecting lower third-party and employee costs.
Administrative expenses fell 26% year-over-year to RMB58.2 million, driven by organizational optimization and cost control.
Loss for the period narrowed 47.5% year-over-year to RMB148.8 million, primarily due to reduced net losses from fair value changes in equity investments and lower operating expenses.
Outlook and guidance
24-week follow-up data from ENSURE Cohort 4 expected in H2 2025; end-of-treatment data from ENRICH and ENHANCE studies anticipated in H1 2026.
Unutilized IPO proceeds expected to be fully deployed by end of 2027, mainly for HBV, HIV, and MDR/XDR programs.
Focus remains on advancing HBV cure regimens to registrational studies and expanding early discovery pipeline.
Ongoing regulatory discussions for phase III trial design, with focus on biomarker-driven patient enrichment and combination regimens.
Company remains committed to expanding patient access in China.
Next Brii Biosciences earnings date
Next Brii Biosciences earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage